A reanalysis of the ATLAS ACS 2-TIMI 51 trial shows rivaroxaban in a different light; cerebral protection may be appropriate in all TAVR procedures, regardless of anatomy; The Feds' big stick vs. carrot approach worked in cutting inappropriate ICD use: and canagliflozin's perported amputation risk didn't make a showing in a real-word study.